Get the Stockscreener App
15.86
3.06%
-0.50
Pre-market:
15.86
Benitec Biopharma Inc stock is traded at $15.86, with a volume of 404.78K.
It is down -3.06% in the last 24 hours and up +14.60% over the past month.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.
See More
Previous Close:
$16.36
Open:
$13.17
24h Volume:
404.78K
Relative Volume:
7.33
Market Cap:
$416.33M
Revenue:
$59,000
Net Income/Loss:
$-21.81M
P/E Ratio:
-1.4482
EPS:
-10.9518
Net Cash Flow:
$-18.07M
1W Performance:
+1.02%
1M Performance:
+14.60%
6M Performance:
+5.38%
1Y Performance:
+45.24%
1-Day Range:
$13.09
$16.31
1-Week Range:
$13.09
$16.68
52-Week Range:
$9.10
$17.15
Benitec Biopharma Inc Stock (BNTC) Company Profile
Name
Benitec Biopharma Inc
Sector
Industry
Phone
(510) 780-0819
Address
3940 TRUST WAY, HAYWARD, CA
Compare BNTC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BNTC
Benitec Biopharma Inc
|
15.86 | 429.46M | 59,000 | -21.81M | -18.07M | -10.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Benitec Biopharma Inc Stock (BNTC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-07-25 | Initiated | TD Cowen | Buy |
| Dec-16-24 | Initiated | H.C. Wainwright | Buy |
| Dec-13-24 | Initiated | Robert W. Baird | Outperform |
| Oct-16-24 | Initiated | Oppenheimer | Outperform |
| Sep-12-24 | Initiated | Guggenheim | Buy |
| Jul-22-24 | Initiated | Leerink Partners | Outperform |
| Jun-13-24 | Initiated | Piper Sandler | Overweight |
| Oct-05-20 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Apr-20-20 | Initiated | Ladenburg Thalmann | Buy |
| Feb-26-16 | Downgrade | Maxim Group | Buy → Hold |
| Dec-31-15 | Reiterated | Maxim Group | Buy |
| Sep-16-15 | Reiterated | Maxim Group | Buy |
View All
Benitec Biopharma Inc Stock (BNTC) Latest News
Can Benitec Biopharma Inc. stock beat analyst upgradesJuly 2025 EndofMonth & Capital Protection Trading Alerts - newser.com
Is Benitec Biopharma Inc. a candidate for recovery playJuly 2025 Weekly Recap & Verified Momentum Stock Ideas - newser.com
Benitec Biopharma appoints former Intra-Cellular CEO to board - Investing.com
Benitec Biopharma appoints former Intra-Cellular CEO to board By Investing.com - Investing.com South Africa
Benitec Biopharma Shares Surge 20% After FDA Grants Fast Track Status for OPMD Gene Therapy - MSN
Is Benitec Biopharma Inc. stock positioned well for digital economyTrade Analysis Summary & Safe Swing Trade Setups - newser.com
Custom strategy builders for tracking Benitec Biopharma Inc.Weekly Loss Report & Free Weekly Chart Analysis and Trade Guides - newser.com
Pattern recognition hints at Benitec Biopharma Inc. upside2025 Winners & Losers & Long-Term Growth Plans - newser.com
Is Benitec Biopharma Inc. stock affected by interest rate hikesFed Meeting & Low Drawdown Trading Techniques - newser.com
Benitec Biopharma (BNTC) Announces Promising Phase 1b/2a Trial R - GuruFocus
Benitec Biopharma’s BB-301 Receives FDA Fast Track - TipRanks
Benitec Biopharma stock soars after FDA Fast Track designation for OPMD drug By Investing.com - Investing.com Nigeria
Benitec Biopharma stock soars after FDA Fast Track designation for OPMD drug - Investing.com Canada
Benitec Biopharma Appoints Dr. Sharon Mates to Board of Directors - TradingView
Benitec Biopharma Provides Positive Interim Clinical Study - GlobeNewswire
Benitec Biopharma to Provide Phase 1b/2a Clinical Study Update for BB-301 in Oculopharyngeal Muscular Dystrophy - GlobeNewswire
Benitec Biopharma (NASDAQ: BNTC) appoints Sharon Mates; led ITI to $14.6B J&J deal - Stock Titan
Can Benitec Biopharma Inc. rally from current levels2025 Momentum Check & Free Community Supported Trade Ideas - newser.com
Strategies to average down on Benitec Biopharma Inc.July 2025 PreEarnings & Accurate Intraday Trade Tips - newser.com
Is Benitec Biopharma Inc. stock attractive for growth ETFsProfit Target & Technical Pattern Based Signals - newser.com
What sentiment indicators say about Benitec Biopharma Inc. stock2025 Trading Recap & Daily Growth Stock Investment Tips - newser.com
Using economic indicators to assess Benitec Biopharma Inc. potentialShare Buyback & Capital Protection Trading Alerts - newser.com
Benitec Biopharma Inc. recovery potential after sell off2025 Earnings Surprises & Safe Swing Trade Setup Alerts - newser.com
Full Stock Market News from 2025-11-02 - Stock Titan
Benitec Biopharma (NASDAQ: BNTC) to Share BB-301 OPMD Study Update in Investor Webcast - Stock Titan
Benitec Biopharma to Provide Phase 1b/2a Clinical Study Update for BB-301 in Oculopharyngeal Muscular Dystrophy - GlobeNewswire Inc.
Benitec Biopharma Inc. stock trendline breakdownJuly 2025 Decliners & Advanced Technical Signal Analysis - newser.com
Chart based analysis of Benitec Biopharma Inc. trends2025 Institutional Moves & AI Powered Market Trend Analysis - newser.com
Is Benitec Biopharma Inc. stock attractive for long term wealth buildingJuly 2025 Catalysts & Scalable Portfolio Growth Ideas - newser.com
Will HYGH stock return to pre crash levels2025 Volatility Report & Fast Exit and Entry Trade Guides - newser.com
Real time social sentiment graph for Benitec Biopharma Inc.Portfolio Profit Report & Growth Oriented Trade Recommendations - newser.com
Benitec Biopharma Inc Stock (BNTC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.64%
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):